<DOC>
	<DOCNO>NCT00756951</DOCNO>
	<brief_summary>Oral Mucositis ( OM ) painful debilitate side effect many drug radiation regiment use treat cancer . This study examine investigational drug SCV-07 's possible application treat Oral Mucositis . Studies show SCV-07 possibly increase broad immune system response , thus lower painful side effect experience treated head neck cancer . The purpose study assess safety tolerability SCV-07 's ability delay onset Oral Mucositis patient receive chemoradiation head neck cancer .</brief_summary>
	<brief_title>Dose Ranging Study Assess Safety Efficacy SCV-07 Delay Onset Severe Oral Mucositis Patients Receiving Chemoradiation Therapy Head Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Subject must body weight le 150 kg screen Have recentlydiagnosed , pathologicallyconfirmed squamous cell carcinoma oral cavity , oropharynx , hypopharynx larynx treat chemoradiation therapy first line treatment ( postoperative patient eligible , surgery &lt; 6 week prior initiation radiotherapy . Plan receive continuous course conventional external beam irradiation Plan receive standard cisplatin chemotherapy regimen Pregnant breastfeeding Have head neck tumor lip , sinus , salivary gland unknown primary tumor Prior radiation head neck Have plan receive cetuximab ( Erbitux ) conjunction chemotherapy Had curative surgery 6 week prior initiation radiotherapy Have current oral mucositis Presence active infectious disease exclude oral candidiasis Chronic immunosuppression Seropositive HIV hepatitis B surface antigen C antibody Used investigational agent within 30 day randomization Have know sensitivity investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>SCV-07</keyword>
	<keyword>Oral Mucositis</keyword>
</DOC>